Bennett debuts as unit of ThermoTrex
Bennett X-Ray will mark its first RSNA meeting as a subsidiaryof ThermoTrex Medical, the division formed in September afterLorad parent ThermoTrex Corp. bought Bennett, of Copiague, NY. Don't expect any major changes in Bennett's RSNA booth, as
Bennett X-Ray will mark its first RSNA meeting as a subsidiaryof ThermoTrex Medical, the division formed in September afterLorad parent ThermoTrex Corp. bought Bennett, of Copiague, NY.
Don't expect any major changes in Bennett's RSNA booth, as ThermoTrexplans to allow Lorad and Bennett to maintain their separate identitieswithin ThermoTrex Medical. The two firms will integrate some oftheir imaging technologies, however.
For example, Bennett is developing a line of radiographic equipmentto be sold through Lorad's sales channels. ThermoTrex said Bennett'sexpertise in radiography was a major factor in the company's acquisitionof Bennett. The Bennett systems will be shown in Lorad's boothand will carry the Lorad label.
Bennett has also made a name for itself in digital mammography,and the company will show its latest work in the area. The companywill debut one of its first full-view digital production units,as well as patient images acquired with the system.
In radiography, Bennett will unveil a trauma C-arm designed tobe mounted on a wall rather than a ceiling, in order to save space.The company will show a new line of R&F and fluoroscopic high-fieldgenerators, as well as a prone stereotactic breast biopsy tableto complement its upright stereotactic system.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
